skip to main content, skip to Quick links, or skip to Search


Contact Information

Phone: 919.513.6690
Fax:  919.513.6669

Hours: Monday-Friday, 8AM-5PM
Regular appointments: 
Drop-offs:     7:30AM-8:30AM
Discharges:   4PM-6PM

The Oncology service is a referral-only service. Once the primary veterinarian calls and sets up the referral, the owner may call and arrange an appointment. If the patient has been seen by our service recently, owners may call Oncology directly to set up an appointment.

General Information

The Terry Center

red Cross Cadeceus

Emergency Service

Main Number: 919.513.6500
Small Animal Emergency: 919.513.6911
Large Animal Emergency: 919.513.6630
Monday-Thursday 5PM-8AM
Friday 5PM-Monday 8AM

Open 24 hours on legal holidays.
No appointment needed.


Transitional Cell Carcinoma of the Lower Urinary Tract in Dogs

What is Transitional Cell Carcinoma?

Transitional cell carcinoma is the most common tumor of the canine lower urinary tract. Scottish Terriers are predisposed to developing this cancer. Transitional cell carcinomas is locally invasive, extending into underlying normal tissues, and has a moderate-high rate of spread to other places in the body (called metastasis).

Diagnostic Testing

Diagnostic tests are recommended to determine which sites in the body are involved. These tests include:


ultrasound 1

Tumors are often located in the trigone area where complete surgical removal is not possible (our surgeons are trying newer more aggressive surgeries that may be an option for some dogs). We have occasionally used definitive radiation therapy to treat transitional cell carcinoma, and if a tumor is small and localized this may be something to consider, although the efficacy of radiation therapy is diminished when used to treat bulky disease. Radiation therapy consists of 19 treatments given on a Mon-Fri schedule. Because of the inability to perform complete surgical removal and the limitations of radiation therapy, treatment often consists solely of chemotherapy. Cisplatin, carboplatin, doxorubicin and mitoxantrone all have reported activity with response rates of approximately 30-35%. In our hospital, chemotherapy is administered with a single drug given at 3-week intervals and the tumor reassessed at 6-week intervals. If/when tumor progression is noted, treatment can be changed to an alternate agent. Chemotherapy drugs work by targeting fast-growing cells; cancer cells divide faster and abnormally compared to normal cells. Because of this, chemotherapy preferentially destroys cancer and spares normal tissues. There is the potential for some normal tissues with rapid growth rates (intestinal lining, bone marrow, hair cells) to be transiently damaged by chemotherapy. However, our goal in treating cancer in animals is quality of life, so the dosages are lower than those used in people. We do not normally see significant toxicity with chemotherapy. There is always some risk when a drug is given for the first time, and the oncologist will discuss what types of side effects may develop and what to watch for. If the pet has no problems the first time they receive a drug, they should have no problems with subsequent treatments of that drug. If the pet experiences any side effects, we address them as needed and lower the dosage of the causative drug for future treatments to prevent recurrent problems.

ultrasound 2

We also recommend piroxicam, an oral Non-Steroidal Anti-Inflammatory Drug (NSAID) which has anti-inflammatory and analgesic properties as well as anti-tumor activity against transitional cell carcinoma. This medication should be given with food and the pet owner instructed to watch for signs of gastrointestinal upset (vomiting, change in stool, etc.). If such signs develop, piroxicam should be discontinued for 3-5 days. Restarting of therapy can then be considered in conjunction with the stomach-protectant misoprostil.

Selected References